Publication policy

We want endorsement by ANZMUSC to indicate that the research question is important, the study design (and conduct) is of the highest scientific quality, and the results are likely to make a significant impact on practice and/or policy. Endorsement from ANZMUSC therefore comes with a set of requirements to protect the ANZMUSC brand.

 The ANZMUSC Publication policy is outlined below:

  • Manuscripts should comply with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals published by the International Committee of Medical Journal Editors and with guidelines for reporting of specific study types such as CONSORT and STROBE.
  • Study manuscripts or theses reporting results obtained from ANZMUSC-endorsed studies (including ANZMUSC endorsed sub-studies) or from post-hoc analyses of an ANZMUSC-endorsed study, require review and endorsement by the ANZMUSC Executive prior to submission for publication or examination.
  • All manuscripts that describe aspects of the conduct (e.g. protocols or statistical analysis plans) or secondary discussion papers of an ANZMUSC-endorsed study must be submitted for review and endorsed by the ANZMUSC Executive prior to submission to a journal for publication. This review may be undertaken by the Chair or Chair-delegate who will determine whether external review is required or whether the Chair or Chair-delegate should recommend endorsement to the Executive without external review.
  • All other manuscripts that are proposed to be published in the name of the group study investigators or the management committee of an ANZMUSC-endorsed study (e.g. editorials or review articles) must be submitted for review and endorsed by the ANZMUSC Executive prior to submission to a journal for publication. Manuscripts proposed to be published on behalf of individuals that do not include study data do not require ANZMUSC endorsement.
  • The default authorship for all ANZMUSC-endorsed study manuscripts is:
    • “The X Study Investigators and the ANZMUSC Clinical Trials Network” or
    • “Listed individuals, the X Study investigators and the ANZMUSC Clinical Trials Network” or
    • “Listed individuals, the X Study investigators, the X Institution and the ANZMUSC Clinical Trials Network”. Other arrangements may be acceptable but must be approved by the ANZMUSC Executive.
  • The default listing of individuals on lists of investigators or study sub-committees is the Chair followed by alphabetical order, unless prospectively agreed by the management committee and approved by the ANZMUSC Chair or Chair-delegate.
  • Identification of contributors on study sub-committees, such as steering, data and safety monitoring, statistical and writing committees will be listed in accordance with the respective journal’s policy. The nomination and appointment of people to these sub-committees will be determined by the study management committee. These subcommittees will comprise of a Chair and other members with the appropriate expertise.
  • All hospitals/centres that participated in the study must be listed in the manuscript or on-line appendix. Individuals who contributed to the conduct of the study at each participating hospital must be listed, and where possible, as collaborators. It is usually the case that this will comprise one or more site Research Coordinator(s) and the Site Investigator(s). Variations to this requirement may be proposed by journals and may be acceptable with approval from the ANZMUSC Chair or Chair-delegate. Participating institutions will be listed alphabetically; individual(s) will be listed alphabetically within each institution, unless agreed by the Management Committee or otherwise as required by the journal.
  • Manuscripts submitted to ANZMUSC for publication endorsement will be reviewed by at least two people, at least one of whom is a voting member of the ANZMUSC All other aspects of the review process for manuscripts are as described for study proposal endorsements above.
  • Prior to submission to a journal, a copy of the final manuscript must be sent or made available to all participating sites. Principal Investigators should be given a reasonable period of time to voice any major concerns to the writing committee.
  • The outcome of submission of an ANZMUSC-endorsed manuscript to a journal must be disclosed to the ANZMUSC Executive Office. Where submission to an alternative journal is planned the name of the new target journal must be provided to the ANZMUSC Executive Office. If an ANZMUSC-endorsed manuscript is neither submitted for publication, nor accepted at any journal for publication, this must be disclosed to the ANZMUSC Executive Office. A copy of all ANZMUSC-endorsed manuscripts that are published must be sent to the ANZMUSC Executive Office.
  • The ANZMUSC Executive reserves the right to withdraw endorsement for publication at any stage of the submission for publication process should the scientific quality of a manuscript be deemed substandard or if conflicts cannot be resolved.
  • Studies not endorsed by ANZMUSC, ‘non ANZMUSC’ studies should not mention ANZMUSC in applications for funding. The Principal Investigator(s) own the study data. Publications and presentations of these studies must make no reference to ANZMUSC, except for acknowledgements where appropriate.